
Memorial Sloan Kettering Cancer Center
Overview
Leading cancer center focused on patient care, research, and education.
Founded
1884
Deals ยท 12mo
0
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Flare Therapeutics | Mar 2023Participated | $123 MSeries B | |
Blue Note Therapeutics | Sep 2021Participated | $5 MSeries A | |
Ajax Therapeutics | Jun 2021Participated | $40 MOther Equity | |
ORIC Pharmaceuticals | Feb 2018Participated | $50 MSeries C | |
COTA Healthcare | Feb 2018Participated | $40 MSeries C | |
Flare Therapeutics | Mar 2023Participated | $123 MSeries B | |
Blue Note Therapeutics | Sep 2021Participated | $5 MSeries A | |
Ajax Therapeutics | Jun 2021Participated | $40 MOther Equity | |
ORIC Pharmaceuticals | Feb 2018Participated | $50 MSeries C | |
COTA Healthcare | Feb 2018Participated | $40 MSeries C |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 0 | 1 |
| Series B | 0 | 1 |
| Series C+ | 0 | 2 |
| Other Equity | 0 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Feb '18 | 2 |
| Mar '18 | 0 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 0 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 0 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 0 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 1 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 1 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 1 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 5 |
| AI & Machine Learning | 1 |
| Space & Frontier Tech | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 1 |
| $10M-$25M | 0 |
| $25M-$50M | 2 |
| $50M-$100M | 1 |
| $100M-$250M | 1 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 1 of 1 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 5 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Boxer Capital | 2 |
| EcoR1 Capital | 2 |
| Agent Capital | 1 |
| Alumni Ventures | 1 |
| Atoc Holdings | 1 |
| Boston Millennia Partners | 1 |
| Casdin Capital | 1 |
| Eli Lilly and Company | 1 |
| Essex Woodlands | 1 |
| Eventide Asset Management | 1 |
| Fidelity Management & Research Company | 1 |
| Foresite Capital | 1 |
| GordonMD Global Investments | 1 |
| Hackensack Meridian Health | 1 |
| Horizon Blue Cross Blue Shield of New Jersey | 1 |
| Inning One Ventures | 1 |
| Invus | 1 |
| IQVIA | 1 |
| JAZZ Venture Partners | 1 |
| Kravis Investment Partners | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 0 | 0% |
| Participating | 5 | 100% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 0 | 0% |
| Co-led | 0 | 0% |
Lead dynamics requires at least one led deal in this range
Team
Director
Scientific Research Manager
Associate Chief Health Informatics Officer
Deputy Physician in Chief, Memorial Hospital
Head, Solid Tumor Oncology
Enid A. Haupt Chair in Pediatric Oncology
Chief Marketing and Communications Officer
Chief Data Officer